Gilead Deal History & Licensing Activity
Gilead is a large pharma. Over the past three years, Gilead has been involved in 11 licensing and acquisition transactions, with a primary focus on Small Molecules (8 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Small Molecules
Focus Area
Infectious Disease
Gilead Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Gilead in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| OM336 | Ouro Medicines | Bispecific Antibodies | Unknown | acquisition | Mar 2026 |
| lenacapavir | U.S. State Department/PEPFAR | Small Molecules | Unknown | license | Sep 2025 |
| lenacapavir | U.S. State Department/PEPFAR | Small Molecules | Unknown | collaboration | Jun 2025 |
Gilead Pipeline Focus
Therapeutic areas and modalities where Gilead is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Gilead Strategic Signals
Key indicators of Gilead's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
- Undisclosed—
Revenue at Risk (LOE)
Patent expirations create urgency for Gilead to replace revenue through in-licensing or acquisitions.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Gilead's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Infectious Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
About Gilead Licensing & Deal Activity
Gilead is a large pharma company that has been actively engaged in licensing transactions across the biopharma landscape. With 11 deals over the past three years, Gilead ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Gilead include Infectious Disease (6 deals and trials), Immunology (3 deals and trials), Oncology (2 deals and trials), and Gastroenterology (2 deals and trials). In terms of modality, Gilead has shown particular interest in small molecules, bispecific antibodies, jakinhibitor.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Gilead and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Gilead's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.